Bibliography
- Ma Q , CavallinLE, YanBet al.: Antitumorigenesis of antioxidants in a transgenic Rac1 model of Kaposi’s sarcoma.Proc. Natl Acad. Sci. USA106(21), 8683–8688 (2009).
- Hassanain HH , IrshaidF, WiselS, SheridanJ, MichlerRE, Goldschmidt-ClermontPJ: Smooth muscle cell expression of a constitutive active form of human Rac 1 accelerates cutaneous wound repair.Surgery137(1), 92–101 (2005).
- Hassanain HH , GreggD, MarceloMLet al.: Hypertension caused by transgenic overexpression of Rac1.Antioxid. Redox Signal.9(1), 91–100 (2007).
- Mutlu AD , CavallinLE, VincentLet al.: In vivo-restricted and reversible malignancy induced by human herpesvirus-8 KSHV: a cell and animal model of virally induced Kaposi’s sarcoma.Cancer Cell11(3), 245–258 (2007).
- Sodhi A , MontanerS, GutkindJS: Does dysregulated expression of a deregulated viral GPCR trigger Kaposi’s sarcomagenesis?.Faseb J.18(3), 422–427 (2004).
- Bais C , SantomassoB, CosoOet al.: G-protein-coupled receptor of Kaposi’s sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator.Nature391(6662), 86–89 (1998).
- Couty JP , Geras-RaakaE, WekslerBB, GershengornMC: Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor signals through multiple pathways in endothelial cells.J. Biol. Chem.276(36), 33805–33811 (2001).
- Montaner S , SodhiA, PeceS, MesriEA, GutkindJS: The Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor promotes endothelial cell survival through the activation of Akt/protein kinase B.Cancer Res.61(6), 2641–2648 (2001).
- Montaner S , SodhiA, ServitjaJMet al.: The small GTPase Rac1 links the Kaposi sarcoma-associated herpesvirus vGPCR to cytokine secretion and paracrine neoplasia.Blood104(9), 2903–2911 (2004).
- Krown SE : Highly active antiretroviral therapy in AIDS-associated Kaposi’s sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi’s sarcoma.J. Clin. Oncol.22(3), 399–402 (2004).
- Northfelt DW , DezubeBJ, ThommesJAet al.: Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: results of a randomized Phase III clinical trial.J. Clin. Oncol.16(7), 2445–2451 (1998).
- Stewart S , JablonowskiH, GoebelFDet al.: Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma. International Pegylated Liposomal Doxorubicin Study Group.J. Clin. Oncol.16(2), 683–691 (1998).
- Gill PS , WernzJ, ScaddenDTet al.: Randomized Phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi’s sarcoma.J. Clin. Oncol.14(8), 2353–2364 (1996).
- Welles L , SavilleMW, LietzauJet al.: Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi’s sarcoma.J. Clin. Oncol.16(3), 1112–1121 (1998).
- Stallone G , SchenaA, InfanteBet al.: Sirolimus for Kaposi’s sarcoma in renal-transplant recipients.N. Engl. J. Med.352(13), 1317–1323 (2005).
Website
- Database S http://seer.cancer.gov/csr/1975_2004/results_merged/sect_10_kaposi_sarcoma.pdf (Accessed 6 February 2008)